<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
  <meta http-equiv="Content-Style-Type" content="text/css" />
  <meta name="generator" content="pandoc" />
  <title></title>
  <style type="text/css">code{white-space: pre;}</style>
</head>
<body>
<h3 id="mondo0017740"><a href="http://purl.obolibrary.org/obo/MONDO_0017740">MONDO:0017740</a></h3>
<p><strong>Label:</strong> disorder of protein N-glycosylation</p>
<p><strong>Subclasses:</strong> <a href="http://purl.obolibrary.org/obo/MONDO_0012117">MONDO:0012117</a> (ALG9-CDG), <a href="http://purl.obolibrary.org/obo/MONDO_0018144">MONDO:0018144</a> (congenital myasthenic syndromes with glycosylation defect),</p>
<p><strong>Corr. equiv. classes:</strong> <a href="http://www.orpha.net/ORDO/Orphanet_79328">Orphanet:79328</a>, <a href="http://purl.obolibrary.org/obo/OMIM_614750">OMIM:614750</a>, <a href="http://purl.obolibrary.org/obo/OMIM_608776">OMIM:608776</a>, <a href="http://purl.obolibrary.org/obo/OMIM_610542">OMIM:610542</a>, <a href="http://purl.obolibrary.org/obo/OMIM_616228">OMIM:616228</a>, <a href="http://purl.obolibrary.org/obo/OMIM_616227">OMIM:616227</a>, <a href="http://purl.obolibrary.org/obo/OMIM_263210">OMIM:263210</a>, <a href="http://www.orpha.net/ORDO/Orphanet_353327">Orphanet:353327</a>,</p>
<p><strong>Class expressions from DL-Learner:</strong></p>
<ul>
<li><a href="http://purl.obolibrary.org/obo/HP_0003473">HP:0003473</a> (Fatigable weakness) and <a href="http://purl.obolibrary.org/obo/HP_0008180">HP:0008180</a> (Mildly elevated creatine phosphokinase) and <a href="http://purl.obolibrary.org/obo/HP_0012759">HP:0012759</a> (Neurodevelopmental abnormality) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003473">HP:0003473</a> (Fatigable weakness) and <a href="http://purl.obolibrary.org/obo/HP_0008180">HP:0008180</a> (Mildly elevated creatine phosphokinase) and <a href="http://purl.obolibrary.org/obo/HP_0012758">HP:0012758</a> (Neurodevelopmental delay) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001270">HP:0001270</a> (Motor delay) and <a href="http://purl.obolibrary.org/obo/HP_0003473">HP:0003473</a> (Fatigable weakness) and <a href="http://purl.obolibrary.org/obo/HP_0008180">HP:0008180</a> (Mildly elevated creatine phosphokinase) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003391">HP:0003391</a> (Gowers sign) and <a href="http://purl.obolibrary.org/obo/HP_0003473">HP:0003473</a> (Fatigable weakness) and <a href="http://purl.obolibrary.org/obo/HP_0008180">HP:0008180</a> (Mildly elevated creatine phosphokinase) and <a href="http://purl.obolibrary.org/obo/HP_0012759">HP:0012759</a> (Neurodevelopmental abnormality) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0003391">HP:0003391</a> (Gowers sign) and <a href="http://purl.obolibrary.org/obo/HP_0003473">HP:0003473</a> (Fatigable weakness) and <a href="http://purl.obolibrary.org/obo/HP_0008180">HP:0008180</a> (Mildly elevated creatine phosphokinase) and <a href="http://purl.obolibrary.org/obo/HP_0012758">HP:0012758</a> (Neurodevelopmental delay) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002515">HP:0002515</a> (Waddling gait) and <a href="http://purl.obolibrary.org/obo/HP_0003473">HP:0003473</a> (Fatigable weakness) and <a href="http://purl.obolibrary.org/obo/HP_0008180">HP:0008180</a> (Mildly elevated creatine phosphokinase) and <a href="http://purl.obolibrary.org/obo/HP_0012759">HP:0012759</a> (Neurodevelopmental abnormality) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002515">HP:0002515</a> (Waddling gait) and <a href="http://purl.obolibrary.org/obo/HP_0003473">HP:0003473</a> (Fatigable weakness) and <a href="http://purl.obolibrary.org/obo/HP_0008180">HP:0008180</a> (Mildly elevated creatine phosphokinase) and <a href="http://purl.obolibrary.org/obo/HP_0012758">HP:0012758</a> (Neurodevelopmental delay) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001288">HP:0001288</a> (Gait disturbance) and <a href="http://purl.obolibrary.org/obo/HP_0003473">HP:0003473</a> (Fatigable weakness) and <a href="http://purl.obolibrary.org/obo/HP_0008180">HP:0008180</a> (Mildly elevated creatine phosphokinase) and <a href="http://purl.obolibrary.org/obo/HP_0012759">HP:0012759</a> (Neurodevelopmental abnormality) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001288">HP:0001288</a> (Gait disturbance) and <a href="http://purl.obolibrary.org/obo/HP_0003473">HP:0003473</a> (Fatigable weakness) and <a href="http://purl.obolibrary.org/obo/HP_0008180">HP:0008180</a> (Mildly elevated creatine phosphokinase) and <a href="http://purl.obolibrary.org/obo/HP_0012758">HP:0012758</a> (Neurodevelopmental delay) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001270">HP:0001270</a> (Motor delay) and <a href="http://purl.obolibrary.org/obo/HP_0003391">HP:0003391</a> (Gowers sign) and <a href="http://purl.obolibrary.org/obo/HP_0003473">HP:0003473</a> (Fatigable weakness) and <a href="http://purl.obolibrary.org/obo/HP_0008180">HP:0008180</a> (Mildly elevated creatine phosphokinase) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001270">HP:0001270</a> (Motor delay) and <a href="http://purl.obolibrary.org/obo/HP_0002515">HP:0002515</a> (Waddling gait) and <a href="http://purl.obolibrary.org/obo/HP_0003473">HP:0003473</a> (Fatigable weakness) and <a href="http://purl.obolibrary.org/obo/HP_0008180">HP:0008180</a> (Mildly elevated creatine phosphokinase) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0001270">HP:0001270</a> (Motor delay) and <a href="http://purl.obolibrary.org/obo/HP_0001288">HP:0001288</a> (Gait disturbance) and <a href="http://purl.obolibrary.org/obo/HP_0003473">HP:0003473</a> (Fatigable weakness) and <a href="http://purl.obolibrary.org/obo/HP_0008180">HP:0008180</a> (Mildly elevated creatine phosphokinase) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0000271">HP:0000271</a> (Abnormality of the face) and <a href="http://purl.obolibrary.org/obo/HP_0003473">HP:0003473</a> (Fatigable weakness) and <a href="http://purl.obolibrary.org/obo/HP_0012759">HP:0012759</a> (Neurodevelopmental abnormality) and <a href="http://purl.obolibrary.org/obo/HP_0040081">HP:0040081</a> (Abnormal levels of creatine kinase in blood) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0000271">HP:0000271</a> (Abnormality of the face) and <a href="http://purl.obolibrary.org/obo/HP_0003473">HP:0003473</a> (Fatigable weakness) and <a href="http://purl.obolibrary.org/obo/HP_0012758">HP:0012758</a> (Neurodevelopmental delay) and <a href="http://purl.obolibrary.org/obo/HP_0040081">HP:0040081</a> (Abnormal levels of creatine kinase in blood) 62.50%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0000271">HP:0000271</a> (Abnormality of the face) and <a href="http://purl.obolibrary.org/obo/HP_0003473">HP:0003473</a> (Fatigable weakness) and <a href="http://purl.obolibrary.org/obo/HP_0008180">HP:0008180</a> (Mildly elevated creatine phosphokinase) and <a href="http://purl.obolibrary.org/obo/HP_0012759">HP:0012759</a> (Neurodevelopmental abnormality) 62.50%</li>
</ul>
</body>
</html>
